2022 drug basket: the most expensive drug - for 30 patients;

Treatment for skin cancer - outdoors

The basket committee discussed 850 technologies and drugs for four months, but finally approved only 150 - at a cost of NIS 550 million.

Those approved treat metastatic breast cancer, lung cancer and diabetes, among others.

Out of the basket remains, among other things, treatment for about 10% of those suffering from severe muscle disease

Meirav Cohen

19/01/2022

Wednesday, January 19, 2022, 2:45 p.m.

• Share on Facebook

• Share on WhatsApp

• Share on Twitter

• Share on Email

• Share on general

• Comments

  Comments

In the video: Campaign to publish the drug basket for 2021 (Walla! NEWS system)

The drug basket discussions for 2022 ended last night (Tuesday) at the end of four months. About 850 medicines and technologies were submitted for the health services basket process this year, with a total cost of more than NIS 3 billion, with the budget amount intended for expanding the basket set at NIS 550 million. The final list, which will be submitted today to Health Minister

Nitzan

Horowitz by the chairman of the basket committee, Prof. Jonathan Halevi, included about 150 drugs and technologies.

The drug for the widest patient population is for liver problems, and is intended for more than 120,000 patients.The most expensive technology that entered the basket this year is FLASH, for diabetics treated with multiple insulin regimens. It costs NIS 48 million and is intended for about 24,000 patients. The technology, which is intended for the widest audience of patients, is for the early detection of genetic diseases, and is intended for 28,000 patients.

On the other hand, the drug Libtio for skin cancer and the drug Soliris for myasthenia gravis for a fatal and severe muscle disease were not included in the basket.

Soliris for myasthenia gravis is intended for patients who do not respond to routine treatment, who make up 10 percent of patients with this disease in Israel.

More on Walla!

Lowering the age of breast cancer tests and a cure for Alzheimer's: The drug basket committee begins work

To the full article

Horowitz and Ash Fiction of the Drug Basket Committee, October (Photo: Flash 90, Avshalom Shashoni)

In the field of oncology, innovative drugs have entered the basket, such as the drug Anharto for patients with metastatic breast cancer in the total amount of more than NIS 30 million, and Tagriso for lung cancer patients. Lowering the age of mammography to age 40 did not enter the basket this year for the third time in a row, even though 25% of breast cancer patients are under age 50 - the age of eligibility for testing by the state.

Technologies that have entered are the Libre Freestyle System for continuous monitoring of type 2 diabetics who inject insulin. The system is already in the basket for type 1 diabetics and the indication has been extended this year to type 2 diabetics who inject insulin. The system monitors sugar levels 24 hours a day and gives information on sugar level trends directly to an application installed on the smartphone linked to it.

A drug for the treatment of short bowel syndrome in children - Gatex - also entered the basket.

Through a unique mechanism of action, Gatex increases the absorption area of ​​the remaining intestine and improves the absorption capacity of food and fluids.

The drug reduces to the point of complete weaning the need for intravenous nutrition over time.

Another drug is expobio for the treatment of multiple myeloma.

The drug has a unique mechanism of action with great potency, which has demonstrated significant efficacy in drug-resistant patients.

• news

• News in Israel

• health

Tags

• Health basket

• Medicines